Leonardo Mastropasqua1, Silvio Di Staso2, Rossella D'Aloisio3, Alessandra Mastropasqua1, Luca Di Antonio1, Alfonso Senatore1, Marco Ciancaglini2, Marta Di Nicola4, Giuseppe Di Martino5, Daniele Tognetto3, Lisa Toto1. 1. Department of Medicine and Science of Ageing, Ophthalmology Clinic, University "G. d'Annunzio" Chieti-Pescara, Chieti 66100, Italy. 2. Department of Life, Health and Environmental Sciences, Ophthalmology Clinic, University of L'Aquila, L'Aquila 67100, Italy. 3. Department of Medicine, Surgery and Health Sciences, Eye Clinic, University of Trieste, Trieste 34129, Italy. 4. Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, University "G. d'Annunzio" Chieti-Pescara, Chieti 66100, Italy. 5. Department of Medicine and Science of Ageing, School of Hygiene and Preventive Medicine, University "G. d'Annunzio" Chieti-Pescara, Chieti 66100, Italy.
Abstract
AIM: To investigate the efficacy and safety of ranibizumab (RZB group) and dexamethasone implant (DEX group) intravitreal treatments in patients with treatment-naïve center involved diabetic macular edema (DME) by means of functional and morphological assessments. METHODS: This retrospective cohort study included 50 eyes of 50 patients with DME treated either with RBZ or DEX. Best-corrected visual acuity (BCVA) and microperimetry were evaluated at baseline and during a 6-month follow-up. In addition, central macular thickness (CMT) by means of structural optical coherence tomography (OCT) and retinal capillary plexus density and choriocapillary density by means of OCT angiography were assessed in all cases. RESULTS: Functional and morphological parameters significantly improved during the study period in both groups. BCVA improved significantly in both groups with a greater increase in the DEX group compared to the RBZ group (P=0.030). Microperimetry significantly differed during follow-up between the two treatments (P=0.031). In both groups CMT significantly decreased (P<0.001) without statistically significant differences between the two groups. A statistically significant increase of deep capillary plexus density was detected in both groups at 30d after therapy. The retreatment rate was 0.70±0.10 and 0.65±0.10 in the RBZ group and 0.65±0.10 and 0.50±0.11 in DEX group at 120 and 180d respectively. Two out of 25 patients in DEX group showed intraocular pressure increase requiring hypotonic eye drops. CONCLUSION: Both treatments are very effective for DME treatment during 6mo of follow-up with a lower retreatment rate in DEX group. International Journal of Ophthalmology Press.
AIM: To investigate the efficacy and safety of ranibizumab (RZB group) and dexamethasone implant (DEX group) intravitreal treatments in patients with treatment-naïve center involved diabetic macular edema (DME) by means of functional and morphological assessments. METHODS: This retrospective cohort study included 50 eyes of 50 patients with DME treated either with RBZ or DEX. Best-corrected visual acuity (BCVA) and microperimetry were evaluated at baseline and during a 6-month follow-up. In addition, central macular thickness (CMT) by means of structural optical coherence tomography (OCT) and retinal capillary plexus density and choriocapillary density by means of OCT angiography were assessed in all cases. RESULTS: Functional and morphological parameters significantly improved during the study period in both groups. BCVA improved significantly in both groups with a greater increase in the DEX group compared to the RBZ group (P=0.030). Microperimetry significantly differed during follow-up between the two treatments (P=0.031). In both groups CMT significantly decreased (P<0.001) without statistically significant differences between the two groups. A statistically significant increase of deep capillary plexus density was detected in both groups at 30d after therapy. The retreatment rate was 0.70±0.10 and 0.65±0.10 in the RBZ group and 0.65±0.10 and 0.50±0.11 in DEX group at 120 and 180d respectively. Two out of 25 patients in DEX group showed intraocular pressure increase requiring hypotonic eye drops. CONCLUSION: Both treatments are very effective for DME treatment during 6mo of follow-up with a lower retreatment rate in DEX group. International Journal of Ophthalmology Press.
Authors: Rohit Varma; Neil M Bressler; Quan V Doan; Michelle Gleeson; Mark Danese; Julie K Bower; Elizabeth Selvin; Chantal Dolan; Jennifer Fine; Shoshana Colman; Adam Turpcu Journal: JAMA Ophthalmol Date: 2014-11 Impact factor: 7.389
Authors: C P Wilkinson; Frederick L Ferris; Ronald E Klein; Paul P Lee; Carl David Agardh; Matthew Davis; Diana Dills; Anselm Kampik; R Pararajasegaram; Juan T Verdaguer Journal: Ophthalmology Date: 2003-09 Impact factor: 12.079
Authors: Giuseppe Querques; Rosangela Lattanzio; Lea Querques; Giacinto Triolo; Maria L Cascavilla; Edoardo Cavallero; Claudia Del Turco; Giuseppe Casalino; Francesco Bandello Journal: Retina Date: 2014-02 Impact factor: 4.256
Authors: Yali Jia; Ou Tan; Jason Tokayer; Benjamin Potsaid; Yimin Wang; Jonathan J Liu; Martin F Kraus; Hrebesh Subhash; James G Fujimoto; Joachim Hornegger; David Huang Journal: Opt Express Date: 2012-02-13 Impact factor: 3.894
Authors: Yali Jia; John C Morrison; Jason Tokayer; Ou Tan; Lorinna Lombardi; Bernhard Baumann; Chen D Lu; Woojhon Choi; James G Fujimoto; David Huang Journal: Biomed Opt Express Date: 2012-11-07 Impact factor: 3.732